GLUE (Monte Rosa Therapeutics) Beginning Cash Position: $134.84 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GLUE Monte Rosa Therapeutics Inc GLUE
32 GF Score
Price $21.97
! 5 Warning Signs
View Full Analysis

What is Monte Rosa Therapeutics Beginning Cash Position?

Monte Rosa Therapeutics GLUE -4.52% 32 Beginning Cash Position is $134.84 Mil as of Mar. 2026. GuruFocus rates GLUE with a GF Score™ of 32/100. The stock has 5 warning signs investors should review.

Monte Rosa Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $134.84 Mil.

Monte Rosa Therapeutics's quarterly Beginning Cash Position increased from Sep. 2025 ($74.38 Mil) to Dec. 2025 ($213.29 Mil) but then declined from Dec. 2025 ($213.29 Mil) to Mar. 2026 ($134.84 Mil).

Monte Rosa Therapeutics's annual Beginning Cash Position increased from Dec. 2023 ($60.19 Mil) to Dec. 2024 ($132.68 Mil) and increased from Dec. 2024 ($132.68 Mil) to Dec. 2025 ($229.12 Mil).

Monte Rosa Therapeutics Beginning Cash Position Related Terms

Monte Rosa Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Monte Rosa Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monte Rosa Therapeutics Beginning Cash Position Chart

Monte Rosa Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 42.86 351.41 60.19 132.68 229.12

Monte Rosa Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 229.12 83.41 74.38 213.29 134.84
GLUE
32GF Score
Monte Rosa Therapeutics Inc GLUE
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monte Rosa Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $134.84 Mil mean?
Monte Rosa Therapeutics (GLUE) has a Beginning Cash Position of $134.84 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Monte Rosa Therapeutics and its competitors.
Is Monte Rosa Therapeutics' Beginning Cash Position too high?
Monte Rosa Therapeutics' current Beginning Cash Position is $134.84 Mil. Overall, Monte Rosa Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Monte Rosa Therapeutics' Beginning Cash Position compare to SNDX and IOVA?
Monte Rosa Therapeutics' Beginning Cash Position of $134.84 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Monte Rosa Therapeutics and its competitors. Monte Rosa Therapeutics's current Beginning Cash Position is $134.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monte Rosa Therapeutics stock overvalued right now?
Monte Rosa Therapeutics (GLUE) has a current Beginning Cash Position of $134.84 Mil. The current Beginning Cash Position is $134.84 Mil. Monte Rosa Therapeutics' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Monte Rosa Therapeutics (GLUE), the current Beginning Cash Position is $134.84 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monte Rosa Therapeutics Business Description

Address 321 Harrison Avenue, Suite 900, Boston, MA, USA, 02118
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
32GF Score

Get the complete analysis for GLUE

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.97
Price